(35 days)
Not Found
No
The device description details a dipstick immunoassay based on chemical reactions and visual interpretation of lines, with no mention of computational analysis, algorithms, or learning processes.
No
The device is a diagnostic test for detecting RSV antigen, intended to aid in diagnosis, not to treat or cure a condition.
Yes
The 'Intended Use / Indications for Use' section explicitly states, "The test is intended for use as an aid in the diagnosis of acute respiratory syncytial viral infections."
No
The device description clearly outlines a physical dipstick immunoassay with reagents and a test strip, indicating it is a hardware-based diagnostic test, not software-only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states it's for the "rapid, qualitative detection of respiratory syncytial virus (RSV) antigen... directly from nasopharyngeal swab, nasopharyngeal aspirate, or nasal/nasopharyngeal wash specimens". This involves testing biological samples taken from the human body.
- Purpose: The test is intended "as an aid in the diagnosis of acute respiratory syncytial viral infections". This is a diagnostic purpose.
- Mechanism: The device description details a "dipstick immunoassay" that reacts with "extracted specimen" to detect "RSV antigens". This is a laboratory-based test performed on a sample outside of the body.
- Specimen Type: It uses "nasopharyngeal swab, nasopharyngeal aspirate, or nasal/nasopharyngeal wash specimens", which are biological samples.
All of these characteristics align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes.
N/A
Intended Use / Indications for Use
The QuickVue RSV test is a dipstick immunoassay which allows for the rapid, qualitative detection of respiratory syncytial virus (RSV) antigen (viral fusion protein) directly from nasopharyngeal swab, nasopharyngeal aspirate, or nasal/nasopharyngeal wash specimens for symptomatic pediatric patients (eighteen years of age and younger). The test is intended for use as an aid in the diagnosis of acute respiratory syncytial viral infections. It is recommended that negative test results be confirmed by cell culture. Negative results do not preclude RSV infection and it is recommended that they not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use.
Product codes (comma separated list FDA assigned to the subject device)
GOG
Device Description
Nasopharyngeal swabs. nasopharyngeal aspirate, and nasal/nasopharyngeal wash serve as specimens for this test. The patient specimen is placed in a tube containing Extraction Reagent, during which time the virus particles in the specimen are disrupted, exposing internal viral After extraction, the Test Strip is antigens. placed in the Extraction Tube for 15 minutes. During this time, the extracted specimen will react with the reagents in the Test Strip.
If the extracted specimen contains RSV antigens, a pink-to-red Test Line along with a blue procedural Control Line will appear on the Test Strip. If RSV viral antigens are not present, or present at very low levels, only a blue procedural Control Line will appear. If no blue procedural Control Line develops, the result is considered invalid.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
eighteen years of age and younger
Intended User / Care Setting
professional and laboratory use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A multi-center field clinical study was undertaken to document the performance characteristics of the test. Sensitivity, specificity and overall accuracy were calculated using nasal/nasopharyngeal wash specimens compared to viral culture.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Study type: multi-center field clinical study.
Nasal/nasopharyngeal wash specimens were compared to viral culture.
Sensitivity, specificity and overall accuracy were calculated.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity, specificity and overall accuracy.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3480 Respiratory syncytial virus serological reagents.
(a)
Identification. Respiratory syncytial virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to respiratory syncytial virus in serum. Additionally, some of these reagents consist of respiratory syncytial virus antisera conjugated with a fluorescent dye (immunofluorescent reagents) and used to identify respiratory syncytial viruses from clinical specimens or from tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of respiratory syncytial virus infections and provides epidemiological information on diseases caused by these viruses. Respiratory syncytial viruses cause a number of respiratory tract infections, including the common cold, pharyngitis, and infantile bronchopneumonia.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
0
APR 2 3 2007
510(k) SUMMARY
Submitted By:
Quidel Corporation 10165 McKellar Court San Diego, California 92121 Telephone: 858-552-7910 858-646-8045 Fax:
Submission Contact: Jennifer Hankard
March 16, 2007 Date Prepared:
Device Trade Name: QuickVue® RSV test
Common Name: Respiratory Syncytial Virus (RSV) Test
QuickVue® RSV test (K061008) Predicate Device:
Device Classification/Name: 21 CFR 866.3480 / Respiratory syncytial virus serological reagents
These tests are used to aid in the diagnosis of disease caused by respiratory syncytial viruses and provides epidemiological information on these diseases (21 CFR 866.3480). The Food classified and Drug Administration has serological test systems for the detection of respiratory syncytial virus as Class I.
Intended Use: The QuickVue RSV test is a dipstick immunoassay which allows for the rapid. qualitative detection of respiratory syncytial virus (RSV) antigen (viral fusion protein) directly from nasopharyngeal swab, nasopharyngeal aspirate, or nasal/nasopharyngeal wash specimens for symptomatic pediatric patients (eighteen years of age and younger). The test is intended for use as an aid in the diagnosis of acute respiratory syncytial viral infections. It is recommended that negative test results be confirmed by cell culture. Negative results do not preclude RSV infection and it is recommended that they not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use.
1
Physiologic Basis of the Test:
Respiratory syncytial virus (RSV) is a single stranded (negative strand) RNA virus of the Paramyxoviridae family. It is the causative agent of a highly contagious, acute, viral infection of the respiratory tract. Nearly half of all children become infected by their first year of life. It is also the major viral cause of nosocomial illness in children already hospitalized for other reasons. In the United States, RSV is estimated to be responsible for 73,400 to 126,300 hospitalizations annually for bronchiolitis and pneumonia alone among children younger than 1 year. In children hospitalized with RSV infection, it is believed to be the most common viral cause of death in children younger than 5 years, particularly in children younger than one year. Among children hospitalized with RSV infection, the mortality rate is estimated to be as low as 0.3% to 1.0% of hospitalized children and in the range of 2.5% to 4.0% for hospitalized children with underlying cardiac or pulmonary disease.
The QuickVue® RSV test is a lateral-flow immunoassay using highly sensitive monoclonal antibodies that are specific for RSV antigens. The test is specific to RSV antigen with no known cross-reactivity to normal flora or other known respiratory pathogens.
Device Description: Nasopharyngeal swabs. nasopharyngeal aspirate, and nasal/nasopharyngeal wash serve as specimens for this test. The patient specimen is placed in a tube containing Extraction Reagent, during which time the virus particles in the specimen are disrupted, exposing internal viral After extraction, the Test Strip is antigens. placed in the Extraction Tube for 15 minutes. During this time, the extracted specimen will react with the reagents in the Test Strip.
If the extracted specimen contains RSV antigens, a pink-to-red Test Line along with a blue procedural Control Line will appear on the Test Strip. If RSV viral antigens are not present, or present at very low levels, only a blue procedural Control Line will appear. If no blue procedural Control Line develops, the result is considered invalid.
2
Device Comparison:
| Features | QuickVue® RSV test
(Proposed) | QuickVue® RSV test
(K061008) |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | The QuickVue RSV test is a dipstick
immunoassay which allows for the
rapid, qualitative detection of
respiratory syncytial virus (RSV)
antigen (viral fusion protein) directly
from nasopharyngeal swab,
nasopharyngeal aspirate, or
nasal/nasopharyngeal wash
specimens for symptomatic pediatric
patients (eighteen years of age and
younger). The test is intended for
use as an aid in the diagnosis of
acute respiratory syncytial viral
infections. It is recommended that
negative test results be confirmed by
cell culture. Negative results do not
preclude RSV infection and it is
recommended that they not be used
as the sole basis for treatment or
other management decisions. The
test is intended for professional and
laboratory use. | The QuickVue RSV test is a dipstick
immunoassay which allows for the
rapid, qualitative detection of
respiratory syncytial virus (RSV)
antigen (viral fusion protein) directly
from nasopharyngeal swab or
nasopharyngeal aspirate specimens
for symptomatic pediatric patients
(eighteen years of age and younger).
The test is intended for use as an aid
in the diagnosis of acute respiratory
syncytial viral infections. It is
recommended that negative test
results be confirmed by cell culture.
Negative results do not preclude
RSV infection and it is recommended
that they not be used as the sole
basis for treatment or other
management decisions. The test is
intended for professional and
laboratory use. |
| Specimen Types | Nasopharyngeal swab,
Nasopharyngeal aspirate, and
Nasal/nasopharyngeal wash | Nasopharyngeal swab and
Nasopharyngeal aspirate |
| Extract / Elute | Extraction reagent used for
swab/aspirate/wash | Extraction reagent used for
swab/aspirate |
| Read Result Time | 15 Minutes | 15 Minutes |
| Format | Lateral-flow immunoassay dipstick | Lateral-flow immunoassay dipstick |
| Control Features | Procedural Control Line
Clearing of background | Procedural Control Line
Clearing of background |
| External Controls | Positive RSV swab
RSV negative swab coated with
Streptococcus C antigen | Positive RSV swab
RSV negative swab coated with
Streptococcus C antigen |
Summary of Performance Data:
A multi-center field clinical study was undertaken to document the performance characteristics of the test. Sensitivity, specificity and overall accuracy were calculated using nasal/nasopharyngeal wash specimens compared to viral culture.
3
Conclusion:
This study demonstrated the substantial equivalence of the QuickVue® RSV test with the addition of the nasal/nasopharyngeal wash specimen type to existing products already marketed. This study further demonstrated the suitability of the product for professional and laboratory use. Clinical studies are a critical element in establishing the fundamental safety and effectiveness of the product and its appropriateness for commercial distribution.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with its wings spread, and three bars below the eagle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Jennifer Hankard Regulatory Affairs Manager Quidel Corporation 10165 McKellar Court San Diego, CA 92121
APR 2 3 2007
Re: K070747
Trade/Device Name: QuickVue® RSV Test Regulation Number: 21CFR 866.3480 Regulation Name: Respiratory syncytial virus serological reagents Regulatory Class: Class I Product Code: GOG Dated: March 16, 2007 Received: March 19, 2007
Dear Ms. Hankard:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the J regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97), Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally, artm
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known):
K 070747
Device Name:
QuickVue® RSV test
Indications for Use:
The QuickVue RSV test is a dipstick immunoassay which allows for the rapid, qualitative detection of respiratory syncytial virus (RSV) antigen (viral fusion protein) directly from nasopharyngeal swab, nasopharyngeal aspirate, or nasal/nasopharyngeal wash specimens for symptomatic pediatric patients (eighteen years of age and younger). The test is intended for use as an aid in the diagnosis of acute respiratory syncytial viral infections. It is recommended that negative test results be confirmed by cell culture. Negative results do not preclude RSV infection and it is recommended that they not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use.
Prescription Use x (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Division Sign-Off | |
|---|---|
| ------------------- | -- |
Office of In Vitro Diagnostic Device Evaluation and Safety
| Page | 1 of 1 |
|---|---|
| 510(k) | K070747 |